4-hydroxypyrazolo (3,4-d) pyrimidine (B.W. 56-158: HPP) is a potent inhibitor of the enzyme xanthine oxidase. It was first used in the treatment of leukaemia to suppress the oxidation of 6-mercaptopurine to the therapeutically inert metabolite 6-thiouric acid, and the observation that it lowered the concentration of uric acid in serum and urine has led to its use in gout (Rundles, Wyngaarden, Hitchings, Elion, and Silberman, 1963; Klinenberg, Goldfinger, Miller, and Seegmiller, 1963) . Fig. 1 shows the chemical structure of HPP; it is an isomer of hypoxanthine and it inhibits the oxidation of the oxypurines hypoxanthine and xanthine to uric acid. The oxypurines are more soluble than uric acid and are excreted in the urine. This paper describes our preliminary experience with HPP in four patients with gout. They were in-patients for the first few weeks of treatment and took a low purine diet during this period.
Serum and urinary uric acids were estimated by Folin's method (Folin and Dennis, 1912-1913) modified for use on the Technicon Autoanalyser; urinary oxypurines were estimated by differential spectrophotometry (Rundles and others, 1963) . The method of serum uric acid estimation has been previously standardized using sera from the population survey of Popert and Hewitt (1962) . The upper limit of normal for males and post-menopausal women is 6 mg./100 ml. and for pre-menopausal women 5 mg./100 ml. 
ANNALS OF THE RHEUMATIC DISEASES
Results The clinical course of the four patients is set out in detail below.
Case 1, an engineer aged 62 years, had a paternal uncle who had suffered from gout and his own gout had started at the age of 14. Acute attacks occurred about twice a year thereafter, although he found that he could often abort them by drinking large quantities of water. From 1952 onwards numerous tophi appeared on the hands, feet, knees, elbows, and ears.
Examination.-On his first admission to hospital in 1962 the serum uric acid was found to lie between 7-7 and 12-5 mg./100 ml. Impairment of renal function was indicated by a blood urea of 116 mg./100 ml. but there was no proteinuria. He was treated with probenecid (Benemid) 1 g. daily. The tophi became smaller and stopped discharging; there were no further attacks of acute gout.
He was re-admitted in December, 1963 , with severe oedema of the legs. The blood pressure was 120/70 and the jugular venous pressure slightly raised at 2 cm. The heart was considerably enlarged; no murmurs were heard but there were numerous ectopic beats and the electrocardiogram showed changes consistent with mild ischaemia. Investigations showed a serum uric acid of 9*2 mg./100 ml.; blood urea 76 mg./100 ml.; proteinuria 24 g. in 24 hours; serum albumin/i -6 g./100 ml.; serum cholesterol 490 mg./100 ml.; haemoglobin 12-2 g.; white blood cells 4,000.
The reason for the nephrotic syndrome was not evident and a renal biopsy (Dr. E. K. M. Smith) showed only a few foci of tubular destruction and fibrosis. Urates could not have been demonstrated in the tissue because of formol fixation, but no crystal spaces were seen. Possible causes considered included the probenecid which he had been taking for a year, and which has been reported to cause the nephrotic syndrome (Ferris, Morgan, and Levitin, 1961) .
Treatment.-For this reason, and because probenecid in daily doses of 1 g. and 2 g. was producing only a moderate fall in serum uric acid (see Fig. 2a, opposite) , it was decided to use HPP. Probenecid was stopped and while the serum uric acid was rising an acute attack of gout occurred in his right knee.
HPP was first given in a dosage of 100 mg. three times daily by mouth. This produced a slow fall in serum uric acid from 12 to 10-1 mg./100 ml. in 6 days. The dose was then doubled and the serum uric acid fell more rapidly, the lowest level being 5 7 mg./100 ml.
To prevent further acute gout (which has been reported following the commencement of HPP treatment) the patient was also given colchicine 2 mg. daily, starting the day before HPP was commenced. On the 12th day of HPP treatment there was diarrhoea and oliguria, the blood urea rising from 90 to 130 mg./100 ml. Colchicine and HPP were both stopped for 3 days, during which time the diarrhoea ceased, the urine output returned to normal and the blood urea fell to its previous level. The serum uric acid level did not rise when HPP was stopped, perhaps because impaired renal function was delaying the latter's excretion. When HPP was recommenced in a dose of 300 mg. daily, the serum uric acid level remained between 6 and 7 mg. per 100 ml. The urinary uric acid level fell during therapy and although the urinary oxypurines rose from 3 mg. to about 60 mg. daily, there was an overall fall in urinary purine excretion from a mean level of 460 mg./24 hrs before treatment to 370 mg./24hrs while HPP was being given (Fig. 2b, opposite) . The addition of probenecid 2 g. daily for 3 days caused a temporary increase in the urinary uric acid but little change in the serum level.
During this admission the oedema disappeared almost completely, proteinuria fell to 2 g. daily, serum albumin rose to 3 -3 g./100 ml. and serum cholesterol fell to 250 mg./100 ml. Reticulocyte counts, bone marrow, and serum alkaline phosphatase remained normal.
Progress.-The patient was discharged in February, 1964, when he was taking 300 mg. HPP daily; 2 weeks later the serum uric acid was 6-8 mg./100 ml. with a urinary uric acid of 280 mg./24 hrs and a urinary oxypurine level of 75 mg./24 hrs.
In April a mild, patchy, dry erythematous rash was observed over the face, arms, and upper thorax (the patient had not noticed it); 2 days later he developed a weeping eruption on the lower abdomen and the periumbilical skin became excoriated. The rash was thought to be due either to a drug reaction or possibly to seborrhoeic dermatitis. HPP was stopped and the rash faded following the use of local hydrocortisone and calamine cream; 6 weeks after the rash had developed HPP was recommenced in a dose of 300 mg. daily and no further untoward reactions have occurred during the 6 weeks which have since elapsed.
Comment.-A patient with tophaceous gout and renal impairment also had the nephrotic syndrome, possibly due to probenecid. HPP 600 mg. daily produced a satisfactory fall in serum uric acid, which was maintained with a dose of 300 mg. daily. HPP may, however, have been a causative factor in the skin eruption which developed several weeks after the drug was started.
Case 2, a housewife aged 72 years, had begun to suffer from gout in 1946 at the age of 54. There was no family history of gout. She had numerous tophi and those on her right middle finger and left little toe were discharging and infected. She was having two acute attacks of gout every year. The only uricosuric therapy had been phenylbutazone for a short period in 1962.
Examination.-The blood pressure was 230/110, the heart was enlarged, and the jugular venous pressure was slightly raised; there was no oedema and physical examination was otherwise normal. The electrocardiogram showed changes of ischaemic heart disease. Blood urea was 59 mg./100 ml.; cholesterol 320 mg./100 ml.; proteinuria 6-7 g. in 24 hrs. 
Treatment.-HPP 300 mg. daily with colchicine 1 mg. daily was started in January, 1964. The serum uric acid level fell rapidly from 12-2 to 5-7 mg./100 ml. with a concomitant fall in urinary urate and a rise in urinary oxypurines. Again the rise in urinary oxypurines did not equal the fall in uric acid excretion (Fig. 3) .
Probenecid 2 g. daily was given for 4 days during HPP treatment; the urinary uric acid level rose but there was no significant increase in oxypurine excretion, and little change in serum uric acid level.
Progress.-After her return home in February, 1964, she remained well on 300 mg. HPP daily and the serum uric acid level (in a different laboratory) was later reported as 3 -3 mg./l00 ml.
In May, 1964, her general practitioner found a mild petechial rash on the arms and back. The HPP was stopped and when she was next seen by us the skin was normal.
Comment.-In a post-menopausal woman with gout the serum uric acid fell satisfactorily on HPP 300 mg. daily, but a rash developed which may have been due to a mild drug reaction.
Case 3, a man aged 50 years, had first had gout in the left great toe in 1952 when he was 38 years old. A tophaceous olecranon bursa had been excised in 1961 after which he developed post-operative gout in the right foot and knee. The most recent acute attack had occurred in October, 1962, but for the 2 months before U.PP 100mg his present admission to hospital in March, 1964, he had had mild continuous pain in both feet.
Examination.-There was a small tophus on the right pinna but physical examination was otherwise normal.
The serum uric acid level on admission was 8 -6 falling to 7-2 mg./100 ml. on a low purine diet. HPP 300 mg. daily then further reduced the serum uric acid to 4 2 mg./100 ml. (Fig. 4, opposite) . Colchicine was not being given and 12 days after treatment began there was an acute attack of gout involving the tophus on his right ear which became red and tender, subsequently discharging tophaceous material. Seven days later an attack of gout occurred in the right ankle joint although he was by now taking colchicine 1 mg. daily as well as HPP, and the serum uric acid level had remained below 5 mg./l00 ml.
When the drug was discontinued there was a rapid rise in serum uric acid to 8 8 mg./100 ml. with an accompanying rise in urinary uric acid. HPP 300 mg. daily was then started again and the serum uric acid level fell to 4-7 mg./lOO ml. While the patient remained on HPP the diet was changed to one of normal purine content, (i.e. just over 2 g. daily), after which the serum uric acid level rose to 6-2 mg./100 ml.
Progress. No tophi were observed. The serum uric acid level was 9-4 mg./100 ml. and blood urea 56 mg./l00 ml. Because uricosuric drugs had previously caused a rash, HPP 300 mg. daily was given with colchicine 1 mg. daily, and the serum uric acid level fell from 9 * 3 to 5 mg./100 ml. (Fig. 5) .
Progress.-Since her discharge she has felt very well apart from occasional aching in both big toes and the serum uric acid level has remained about 4* 5 mg./100 ml.
Comment.-A post-menopausal woman with gout, renal stones, and mild renal failure, had developed skin rashes with probenecid, phenylbutazone, and sulphinpyrazone, but she tolerated HPP 300 mg. daily with no side-effects, and the serum uric acid level fell satisfactorily.
Discussion
The results in these four patients confirm that HPP effectively lowers the levels of serum and urinary uric acid. As the oxidation of xanthine and hypoxanthine is suppressed their urinary levels rise, but in our experience, as in that of Rundles and others (1963) (but not in that of Klinenberg and others, 1963) , this does not replace the fall in urinary uric acid, i.e. there is an overall fall in purine excretion. Significant tissue retention of oxypurines is unlikely, since Rundles and his coleagues found that the rise in serum concentration was slight (about 0 15 mg. to 0 3 mg./100 ml.). Other possibilities are that the oxypurines are re-utilized or that HPP also has an inhibiting effect on purine metabolism at an earlier stage.
No serious harmful effect of HPP has yet been encountered. In two of the four patients a skin eruption followed the commencement of treatment and, although it was not conclusively shown to be due to the drug in either case, this must be regarded as probable. Further experience, however, indicates that the incidence of this complication is not likely to be as high as these first figures suggest. Following the study of the four patients described here, a long-term therapeutic trial to compare the effects of HPP against those of probenecid has been started in patients who have not previously received uricosuric treatment; 3 months after starting the trial eleven patients are so far taking HPP and twelve probenecid; only one of the HPP patients has a mild rash, which developed the day after he began taking the tablets.
Case 3 had two attacks of acute gout shortly after starting treatment. In the comparative trial two of the patients taking HPP have also had acute gout, but so have two of the patients starting probenecid.
The development of gout may be related to the effect of a falling serum uric acid rather than to the particular drug used. In such a situation a tophus, previously more or less in equilibrium with the surrounding tissue fluid, starts to go into solution. Owing to fluctuations in tissue fluid concentration of uric acid there will be small foci of re-crystallization in the vicinity. Such deposition will then produce the inflammatory reaction of gout, perhaps by the mechanism of phagocytosis suggested by Seegmiller and Howell (1962) .
It is too early yet to assess the place of HPP in the treatment of gout and hyperuricaemia. On'ly further observation will tell if such theoretical possibilities as xanthine renal stone formation (Klinenberg and others, 1963) or haemochromatosis (Ayvazian, 1964) 
